BioActor tests Pixience’s 3D skin-imaging software in new clinical trial on a nutricosmetic ingredient
The study will use Pixience’s C-Cube device, which takes both 2D and 3D images of the skin to let researchers better assess changes in skin-health indices like inflammation and pigmentation.
Nutraceutical ingredients supplier BioActor (Maastricht, Netherlands) announced it is partnering with healthcare technology company Pixience (Toulouse, France) to test out Pixience’s innovative C-Cube device to capture skin images in a clinical study that BioActor is running on a nutritional bioactive ingredient.
The study will use Pixience’s C-Cube device, which takes both 2D and 3D images of the skin to let researchers better capture and assess changes in skin-health indices like inflammation and pigmentation. “The unique combination of 2D and 3D measurements allows for the quantitative analysis of the smallest variations in skin relief and microrelief as well as pigmentation analysis,” states Pixience’s website.
C-Cube can measure the depth and width of wrinkles and enable researchers to evaluate the effect of certain products on pores, scars, and skin texture. Researchers can then utilize Pixience’s QuickScale software to analyze measurement data collected using C-Cube, including 3D images.
The new clinical study using C-Cube is on an oral-supplement product. Researchers will be able to test and validate the use of Pixience in the clinical study. The beta-testing in this study will help Pixience refine what it plans to market as its C-Cube Clinical Research Edition software. “Pixience will provide technical assistance to BioActor for the skin image analysis in this new clinical study,” the companies’ press release states.
“BioActor is delighted to work with Pixience as Pixience has developed a best-in-class skin-imaging and -analysis technology that will allow us to further improve our skin-health-for-nutrition platform,” said Hans van der Saag, CEO of BioActor, in a press release.
Sebastian Mangeruca, CEO of Pixience, added, “We have initially developed our C-Cube and QuickScale suite of technologies for the evaluation of topical cosmetic products. BioActor’s experience in running clinical studies nutrition and its active program around nutrition and skin health makes them an ideal partner for testing and validating our C-Cube Clinical Edition for nutrition studies.”
Rousselot to showcase new collagen peptide research and targeted solutions at Vitafoods Europe 2024
April 25th 2024The company will be highlighting new research that demonstrates the ability of its Peptan collagen peptide brand to support sleep quality, reduce gastrointestinal discomfort, and enhance skin health, including density, hydration, and elasticity.
